A prospective, multicenter, large sample registry-based study of Angong Niuhuang Pills for Stroke

A prospective, multicenter, large sample, registry-based clinical trial design to evaluate the efficacy and safety of Angong Niuhuang Pill in the acute phase of stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2100005305

Enrollment

Unknown

Registered

2021-09-14

Start date

2021-10-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The subject was clinically diagnosed with acute stage of stroke and the responsible lesion (infarct or hemorrhage foci) appeared on imaging, and the subject was prescribed Angong Niuhuang Pills for more than 3 days. 2. The Chinese medicine diagnosis is phlegm-heat internal closure evidence 3. Subjects voluntarily enrolled in this study and signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with stroke caused by brain tumor, traumatic brain injury, hematological disease, rheumatic heart disease, coronary heart disease and other heart disease combined with atrial fibrillation. 2. Other patients who are considered by the investigator to be inappropriate for participation in this study.

Design outcomes

Primary

Measure	Time frame
NIHSS;Modified Rankin Scale;	—

Countries

China

Contacts

Public ContactLukui Chen

18761886190@163.com18761886190

Outcome results